



GOG PARTNERS CONNECTION

A Quarterly Newsletter

From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission:
Transforming the standard of care in gynecologic oncology

THE GOG FOUNDATION, INC. AND GOG PARTNERS 2024 YEAR IN REVIEW

Thomas Herzog, MD, President, The GOG Foundation, Inc.

As I reflect on the 2024 calendar year and my first full year as President of the GOG Foundation (GOG-F), I am filled with gratitude and appreciation for the support and guidance I've received from so many of you. It has been an inspiring year since I took office in Chicago in July of 2023. I want to start by acknowledging the incredible dedication of the G8 and our GOG-F staff. Collectively, I am inspired everyday by your commitment to excellence and to our mission. Special thanks to Dr. Copeland, whose guidance has set a high bar for our organization. I also want to extend my deep thanks to our NRG leadership team. Additionally, I want to acknowledge our Investigator Council (IC) and all our committee leaders, whose unwavering support has been invaluable in this first year of my tenure. Critical to our success are our clinical trialists and the staff that support them and our patients at each of our sites, without you we could not fulfill our mission. Together, we have made great strides, and I look forward to continuing this journey with you all.



This year, I have focused on listening and learning from everyone involved in our work. I've engaged with not only the dedicated members of the GOG-F but also our external partners and stakeholders, gaining valuable insights into both our strengths and areas where we can improve. We've achieved several milestones, including FDA approvals across all three major disease areas in gynecologic cancers, the appointment of Dr. Bhavana Pothuri as Director of Diversity & Health Equity for Clinical Trials, and the publication of our White Paper on Diversity in Clinical Trials. You can find this valuable education in the [diversity section on our website](#). We have also expanded our educational initiatives, enhanced international collaborations, and strengthened relationships with key partners such as SGO, FWC and IGCS. These accomplishments reflect our collective efforts, and we will continue to build

upon these successes as we move forward.

Engaging young investigators, fellows, and residents in the GOG-F is critical to ensuring the future of clinical trial research and advancing the next generation of leaders in gynecologic oncology. By providing mentorship and support through programs like the GOG Scholar and New Investigator Program, we foster a pipeline of talented researchers who are equipped to drive innovation and improve patient care. Additionally, the GOG Fellows Forum, which will take place in Miami Beach, Florida this April, offers an invaluable opportunity to engage with and inspire the emerging clinical trialists who will shape the future of our field. Our ongoing collaboration with SGO and FWC on the joint BRIDGES 2.0 initiative further amplifies our commitment to developing these future leaders, expanding their professional networks, and empowering them to contribute meaningfully to research efforts. And furthermore, our team overseeing the management of the Western Association of Gynecologic Oncology (WAGO) expands our reach to engage fellows, residents and young scientists. These initiatives are vital for the continued growth and success of the GOG-F, ensuring that we nurture the next generation of clinical trial researchers who will carry our mission forward.

Our clinical trial program is expanding thanks to advancements in drug development and innovative clinical trial design in collaboration with our pharmaceutical partners, who I also want to thank for their faith in partnering with us. Our GOG-P Investigator Initiated Trials (IIT) program has provided opportunities for investigators to conduct trials that aim to transform the standard of care. As we approach our 100th study, we remain committed to identifying potential new treatments to improve women's health.

Looking ahead, my vision for the GOG-F is centered around fostering inclusivity, innovation, and transparency. I believe that by promoting diversity in leadership, gender equality and authorship opportunities, we can cultivate an even stronger and more collaborative organization. We will continue to refine our clinical trial processes to ensure that we meet the needs of our sites and address challenges like efficient study start-up and robust enrollment. Your feedback will be crucial in this effort, and I encourage you to share your thoughts as we strive to make meaningful improvements. Our mission, grounded in the solidarity and loyalty we share, has positioned us to continue to transform the standard of care. As we evolve, we will ensure that every voice is heard and that our legacy of excellence continues to guide us toward a future of progress and success.

Thank you for your ongoing commitment and support. Together, we are an extraordinary organization!

Happy Holidays to each of you.

With warmest regards,
Tom

THE GOG FOUNDATION, INC. STATEMENT ON THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE (NASEM) REPORT

The GOG Foundation, Inc., (GOG-F) commends the National Academies, Science Engineering, Medicine (NASEM) committee's important research report⁽¹⁾, outlining the need for the NIH Office for Women's Health Research to prioritize women's⁽¹⁾ health disparities and funding to continue important research that persist across various domains, particularly in women's health and gynecologic oncology.

Despite the long history for the need for women's health research, funding remains woefully inadequate, with only 7.9% funding in 2023, a significant decrease from 9.7% of total spending in 2013 of the NIH budget allocated to women's health-related research⁽²⁾. This deficit highlights the urgency for action.

The GOG-F recognizes the profound implications of these findings, and we stand committed to being part of the solution addressing the unmet needs in women's health research. We see the report as an important call to action, urging greater investment and focus in this area. Our organizational vision to "transform the standard of care in gynecologic cancers" clearly aligns with the need to bridge these research gaps. The GOG-F will remain dedicated to expanding clinical trial opportunities, ensuring the continued advancement of groundbreaking and practice changing studies in gynecologic oncology, striving to reduce health disparities for all, thereby improving outcomes for generations to come.

(1): <https://www.nationalacademies.org/our-work/assessment-of-nih-research-on-womens-health>

(2): <https://www.science.org/content/article/nih-needs-new-institute-women-s-health-research-expert-panel-says>



[ACCESS NASEM REPORT](#)

NATIONAL GYNECOLOGIC ONCOLOGY FELLOWS FORUM 2025 ANNUAL CALL FOR ABSTRACTS

The Fellows Forum Program Committee is now accepting abstract submissions for consideration. **The deadline to submit is Monday, January 6, 2025 at 11:59 pm ET.** The submissions deadline will NOT be extended. Incomplete submissions will not be considered.



[Click here](#) to review the Abstract Submission Rules & Regulations prior to submitting your abstract.

The 2025 Program Committee will review all abstracts submissions to oral presentations through a blinded peer-review process. Abstract notification

letters will be sent via email in late-January

[SUBMIT ABSTRACT NOW](#)

[Click here](#) for more information about the Fellows Forum 2025 Annual Meeting taking place **April 2 - 5, 2025** in Miami Beach, Florida at the Fontainebleu Miami Beach Hotel.

IN THE NEWS

GOG-3086 (REFRaME-01) Press Release

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRaME-O1 Trial in Platinum Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the selected dose from the dose-optimization portion (Part 1) of REFRaME-O1, the registration-directed trial of luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC), following a meeting with the U.S. Food and Drug Administration (FDA).

"The topline results confirm luvelta's favorable safety and efficacy profile at the starting dose of 5.2 mg/kg, further supporting our confidence that it can improve clinical outcomes compared to chemotherapy in our ongoing registrational trial," said Anne Borgman, M.D., Sutro's Chief Medical Officer. "Consistent response rates were observed in patients across all levels of FRα expression of 25% or greater, reconfirming luvelta's potential to expand the benefit of a targeted treatment to 8 out of 10 PROC patients."

[Click here](#) to view the press release.



CELEBRATING 2 YEARS
GOG-3045 | MIRASOL

Mirvetuximab Soravtansine was first granted FDA accelerated approval in November 2022 and the conversion to full approval is based on data from the confirmatory Phase 3 MIRASOL trial.



"As the first treatment to show a statistically significant overall survival benefit in patients with platinum-resistant ovarian cancer, Mirvetuximab Soravtansine provides an effective new option for patients with folate receptor alpha positive tumors. These patients previously had very limited options and Mirvetuximab Soravtansine changes that."

Kathleen Moore, MD
MIRASOL principal investigator
Stephenson Cancer Center, University of Oklahoma



CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 21 clinical trials

- 10 Ovary
- 3 Cervix
- 8 Endometrium



To search active trials visit our website by clicking Clinical Trials button below.

Clinical Trials

UPCOMING INDUSTRY MEETINGS

NRG Oncology 2025 Winter Semiannual Meeting



The NRG Winter 2025 Semiannual Meeting will be held in person at the Phoenix Convention Center in Phoenix, AZ, from **January 16, 2025 - January 18, 2025**

NRG Oncology will offer a full program that includes scientific sessions, engaged educational session for early-career investigators, and opportunities for networking events. We are excited to offer an expanded Winter Symposium. Learn more about the full program on the [Agenda & Session Information page](#) (COMING SOON). Select sessions will be held virtually on January 13, 2025 - January 14, 2025, ahead of the meeting.

[Click here](#) for more information on the NRG Oncology 2025 Winter Meeting.

GOG Highlight Reel - January 2025



The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend The GOG Highlight Reel -January 2025 education program presented in person at the **Renaissance Phoenix Downtown Hotel on Saturday, January 18, 2025 from 9:30 am – 11:30 am AZ Time.**

The January 2025 Highlight Reel will be offered in person only.

[Click here](#) for more information on the GOG Highlight Reel - January 2025.

2025 Celebration of Champions

The GOG Foundation, Inc. (GOG-F) is excited to



support the Foundation for Women's Cancer (FWC) for the 2025 Celebration of Champions that will be held at the PGA National Resort in Palm Beach Gardens, Florida on **Saturday, January 25, 2025**.

Featuring experts in the field of gynecologic cancers and beyond, in support of the Foundation for Women's Cancer & Move4her.

[Click here](#) to learn more and to buy your tickets today!

SGO 2025 Winter Meeting

The SGO 2025 Winter Meeting will be held at the Fairmont Chateau Whistler in Whistler, BC, Canada, from **January 30, 2025 - February 1, 2025**



The SGO Winter Meeting fosters collaboration among researchers at all career stages through specialized scientific sessions, insightful posters, and intimate networking events. Attendees can also enjoy exciting winter and wellness activities, blending professional growth with a relaxing retreat. The meeting's close-knit atmosphere creates a unique environment for building connections with established leaders in gynecologic oncology.

[Click here](#) for more information on the SGO 2025 Winter Meeting!

ESGO 2025 Congress

The ESGO 2025 Congress will be held at the Centro Congressi Roma La Nuvola in Rome, Italy, from **February 20- 23, 2025**.



ESGO 2025 will be a celebration of discovery and late-breaking research, new guidelines, practical demonstrations, and exclusive live surgery transmissions you don't want to miss.

The 26th Congress of the European Society of Gynaecological Oncology will bring together over 2,500 attendees from around the world for gathering of learning, networking, and sharing the latest developments in the field of Gynaecological Cancers—all with the goal of enhancing your knowledge, accelerating your skills and advancing the field.

[Click here](#) for more information on the ESGO 2025 Congress!

**HAPPY HOLIDAYS FROM
THE GOG FOUNDATION, INC. AND GOG
PARTNERS**

GOG FOUNDATION[®]
Transforming the experience of care

GOG PARTNERS

**Wishing You A
Safe, Healthy, and
Happy Holiday Season!**



GOG Foundation Inc. | Four Penn Center 1600 JFK Blvd. Suite 1020 | Philadelphia, PA
19103 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!